The effect of melatonin on cisplatin-induced nephrotoxicity: A pilot, randomized, double-blinded, placebo-controlled clinical trial

Ghadrdan, Elliyeh; Sadighi, Sanambar; Ebrahimpour, Sholeh; Abdollahi, Alireza; Hadjibabaei, Molouk; Gholami, Kheirollah; Jahangard‐Rafsanjani, Zahra

doi:10.1016/j.eujim.2020.101065

Cited by 8 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, 11 cases of AKI episodes (16.7%) happened in both melatonin and control groups. The rate of AKI occurrences was in accordance with other previous studies which have been reported 8-40% ( 7 20 ). The contributing factors such as differences in AKI definition, baseline hydration protocols and renal function as well as differences in demographic characteristics and performance status of enrolled patients led to the different incidence of CisIN.…”

Section: Discussionsupporting

confidence: 92%

“…Previously published studies noted NGAL urinary levels increase as soon as 12-24 h after cisplatin infusion in patients who were facing AKI episodes ( 7 20 ). Our finding was compatible with the results of Shahbazi et al .…”

Section: Discussionmentioning

confidence: 99%

“…In 2020 for the first time in a pilot, randomized, double-blinded, placebo- controlled clinical trial, the nephroprotective effects of 20 mg/day melatonin have been examined by Ghadrdan et al . ( 20 ). They collected urine samples at baseline, 6, and 24 h following cisplatin administration to access NGAL, kidney injury molecule-1 (KIM-1) and SCr.…”

Section: Discussionmentioning

confidence: 99%

“…Our study has several differences from Ghadrdan et al . study ( 20 ), especially in terms of methodology, duration of follow-up and endpoints.…”

Section: Discussionmentioning

confidence: 99%

“…The powerful antioxidant effects of melatonin were noted to be in high concentrations of melatonin in melatonin doses higher than 20 mg/day ( 20 ). The lack of previous clinical studies, the fear of daytime drowsiness adverse effects and the information about the range of antioxidant dose of melatonin has resulted in selecting administration of 20 mg/day melatonin for our study.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Melatonin in the prevention of cisplatin-induced acute nephrotoxicity: a randomized, controlled clinical trial

et al. 2022

View full text Add to dashboard Cite

Background and purpose: Cisplatin-induced nephrotoxicity (CisIN) remains the most dose-limiting adverse effect of its clinical use. The protective effects of melatonin on CisIN have been addressed in several non- clinical and animal studies. This study aimed at investigating the potential effects of melatonin on the prevention of CisIN in human. Experimental approach: Our study was a randomized controlled clinical trial, performed on 66 eligible patients in two groups of melatonin or control (no intervention). Melatonin was administrated daily at a dose of 20 mg for 5 days to the patients receiving cisplatin-containing regimens along with the standard protocol of CisIN prevention. Patient demographic information, blood and urinary indices of nitrogen, creatinine, and electrolytes such as sodium, potassium, magnesium as well as neutrophil gelatinase-associated lipocalin were measured in both groups at the baseline, 24 h and five days after melatonin administration. Findings/Results: Cisplatin administration resulted in significant magnesium and potassium loss in patients with cancer. In comparison with the control group, the prevalence of acute renal injury and the rate of urinary magnesium and potassium loss improved with melatonin administration; however, the results were not statistically significant. Tolerable side effects such as daytime drowsiness, nausea, and vomiting were reported in the melatonin group. Conclusion and implications: Although pretreatment with melatonin led to amelioration in urinary electrolyte loss due to CisIN, it failed to show a positive result on acute renal injury prevention. Future well-designed studies with a longer duration of follow-up, larger sample sizes, and higher doses of melatonin are warranted.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Our study has several differences from Ghadrdan et al . study ( 20 ), especially in terms of methodology, duration of follow-up and endpoints.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%